Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.61 |
| ▸ | IGLV6-57 | P01721 | 6/20 | 0.61 |
| ▸ | GLA | P06280 | 5/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | ATM | Q13315 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CASP1 | P29466 | 3/20 | 0.61 |
| ▸ | CASP7 | P55210 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964558 | 0.84 | ALDH1A1 (0.72) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD | |
| SCHEMBL22265905 | 0.84 | ALDH1A1 (0.68) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD | |
| SCHEMBL22927922 | 0.80 | ALDH1A1 (0.61) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD | |
| SCHEMBL67108 | 0.76 | ALDH1A1 (1.00) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD | |
| SCHEMBL29362472 | 0.76 | ALDH1A1 (1.00) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD | |
| SCHEMBL384286 | 0.76 | ALDH1A1 (1.00) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD | |
| SCHEMBL6690441 | 0.76 | ALDH1A1 (0.73) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD | |
| SCHEMBL1942067 | 0.75 | ALDH1A1 (1.00) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD | |
| SCHEMBL5964617 | 0.75 | ALDH1A1 (0.71) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD | |
| SCHEMBL12651810 | 0.75 | ALDH1A1 (1.00) | ALDH1A1IGLV6-57GLAL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-20060008907-A1 | Control of gene expression via light activated RNA interference | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2006-01-12 | — | — | US | disclosed |
| US-6818454-B2 | MONITORING PHOSPHORYLATION STATES OF ONE OR MORE PROTEINS; OBTAIN PROTEIN SAMPLE, INCUBATE WITH LABEL, MONITOR SAMPLE FOR SIGNAL FROM BOUND PROTEINS | BATTELLE MEMORIAL INSTITUTE | 2004-11-16 | — | — | US | disclosed |
| WO-2002066988-A2 | PHOSPHOPROTEIN BINDING AGENTS AND METHODS OF THEIR USE | BATTELLE MEMORIAL INSTITUTE (US) | 2002-08-29 | — | — | WO | disclosed |
| US-20020119505-A1 | Phosphoprotein binding agents and methods of their use | U.S. DEPARTMENT OF ENERGY | 2002-08-29 | — | — | US | disclosed |
| US-5686310-A | Method for determination of the amount of either phosphotyrosine or phosphoserine in a protein | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1997-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | ALDH1A1 2240/4885IGLV6-57 3616/4885GLA 4273/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | ALDH1A1 785/4885IGLV6-57 1628/4885GLA 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.